Scopolamine

Revision as of 19:14, 12 July 2017 by ClaireLewis (talk | contribs) (→‎Administration)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Anticholinergics, Cycloplegic
  • Dosage Forms:
  • Routes of Administration: scopolamine- transdermal. Scopolamine hydrobromide- IV, oral, Ophthalmic
  • Common Trade Names:

Adult Dosing

  • 0.32-0.1mg IV/IM/SubQ
  • 0.4-0.8mg PO
  • 1-2 drops (0.25% ophthalmic solution) up to 4 times daily
  • 1 transdermal patch q72h (each 1.5mg patch delivers 1mg scopolamine over 72h)

Pediatric Dosing

  • Sedation:
    • 6mo-3y: 0.1-0.15 mg IM/IV/subQ
    • 3-6y: 0.2-0.3 mg IM/IV/subQ
  • Vomiting: 6 mcg/kg subQ
  • Transdermal patch not FDA-approved for children

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: infant risk is minimal
  • Renal dosing: contraindicated in renal impairment
  • Hepatic dosing: contraindicated in hepatic impairment

Contraindications

  • Allergy to class/drug
  • Glaucoma
  • Chronic lung disease (repeated doses)
  • Prostatic hypertrophy
  • Pyloric obstruction

Adverse Reactions

Serious

  • Tachyarrhythmia
  • Hallucinations, confusion
  • Glaucoma
  • Systemic absorption of ophthalmic formulation

Common

  • Dry skin, diminished sweating
  • Xerostomia
  • Amnesia, somnolence
  • Mydriasis, blurred vision
  • Local irritation

Pharmacology

  • Half-life: 9.5h (transdermal)
  • Metabolism:
  • Excretion:

Mechanism of Action

  • Belladonna alkaloid with anticholinergic (predominantly antimuscarinic) properties

Comments

See Also

References

Authors: